Case number 1:22-cv-00092
Neurocrine Biosciences, Inc. v. Teva Pharmaceuticals, Inc. et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Mar 30, 2023 | 21 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s). (Attachments: # 1 Stipulated Consent Judgment)(mdb) (Entered: 03/30/2023) (Stipulated Consent Judgment) (2) |
| Mar 30, 2023 | 21 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s). (Attachments: # 1 Stipulated Consent Judgment)(mdb) (Entered: 03/30/2023) (Main Document) (1) |
| Apr 19, 2022 | 20 | Scheduling Order (21) Docket Text: SCHEDULING ORDER: These matters are consolidated for all purposes and all filing shall be made in the lead action, C.A. No. 21-1042 (MN), only. Joinder of Parties due by 1/13/2023. Amended Pleadings due by 1/13/2023. Fact Discovery completed by 1/20/2023. Opening Expert Reports due by 7/17/2023. Rebuttal Expert Reports due by 8/28/2023. Reply Expert Reports due by 9/25/2023. Expert Discovery due by 11/3/2023. Claim Construction Opening Brief served by 3/23/2023. Claim Construction Answering Brief served by 4/20/2023. Claim Construction Reply Brief served by 5/10/2023. Claim Construction Surreply Brief served by 5/26/2023. Joint Claim Construction Brief filed by 6/2/2023. A Markman Hearing is set for 6/23/2023 at 11:00 AM in Courtroom 4A before Judge Maryellen Noreika. A Pretrial Conference is set for 12/18/2023 at 04:30 PM in Courtroom 4A before Judge Maryellen Noreika. A 9-day Bench Trial is set for 1/2/2024 at 08:30 AM in Courtroom 4A before Judge Maryellen Noreika. Signed by Judge Maryellen Noreika on 4/19/2022. (dlw) |
| Apr 19, 2022 | N/A | Create Case Association (0) Docket Text: Case associated with lead case: Create association to 1:21-cv-01042-MN. (dlw) |
| Apr 13, 2022 | 19 | Proposed Order (21) Docket Text: PROPOSED ORDER // Scheduling Order by Neurocrine Biosciences, Inc. (Balick, Steven) Modified on 4/14/2022 (dlw). |
| Apr 13, 2022 | 18 | Letter (1) Docket Text: Letter to The Honorable Maryellen Noreika from Steven J. Balick regarding the Parties' Jointly Proposed Scheduling Order. (Balick, Steven) |
| Apr 12, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED re (25 in 1:21-cv-01148-MN, 19 in 1:21-cv-01067-MN, 27 in 1:21-cv-01043-MN, 16 in 1:21-cv-01408-MN, 19 in 1:21-cv-01042-MN, 26 in 1:21-cv-01553-MN, 30 in 1:21-cv-01118-MN, 18 in 1:21-cv-01464-MN, 17 in 1:22-cv-00092-MN) Stipulation Extending Time to File Revised Proposed Scheduling Order to 4/13/2022. ORDERED by Judge Maryellen Noreika on 4/12/2022. (dlw) |
| Apr 11, 2022 | 17 | Stipulation (5) Docket Text: STIPULATION Seeking to Extend the Deadline for Submission of a Revised Proposed Scheduling Order, by Neurocrine Biosciences, Inc.. (Balick, Steven) |
| Apr 5, 2022 | 16 | Transcript (20) Docket Text: Official Transcript of Teleconference held on 04/04/2022 before Judge Maryellen Noreika. Court Reporter/Transcriber Dale C. Hawkins,Email: Dale_Hawkins@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 4/26/2022. Redacted Transcript Deadline set for 5/6/2022. Release of Transcript Restriction set for 7/5/2022. (dh) |
| Apr 4, 2022 | 15 | SO ORDERED (6) Docket Text: SO ORDERED, re (22 in 1:21-cv-01148-MN, 24 in 1:21-cv-01043-MN, 14 in 1:22-cv-00092-MN) Stipulation and Order Dismissing Defendant Teva Pharmaceutical Industries Ltd. Without Prejudice and Amending Caption to Reflect Same filed by Neurocrine Biosciences, Inc., Party Teva Pharmaceutical Industries Ltd. terminated. Signed by Judge Maryellen Noreika on 4/4/2022. Associated Cases: 1:21-cv-01043-MN, 1:21-cv-01148-MN, 1:22-cv-00092-MN(mdb) |
| Apr 4, 2022 | N/A | Scheduling Conference (0) Docket Text: Minute Entry for proceedings held before Judge Maryellen Noreika - Scheduling Telephone Conference held on 4/4/2022. Discussion regarding the proposed schedule and disputes raised in the parties' proposal. A Markman Hearing is set for 6/23/2023, the Pretrial Conference will be set in December 2023 once the revised proposed schedule is filed, and a 9-day Bench Trial is set for 1/2/2024. The defendants are limited to three motions in limine collectively; if they wish to file more than three, they must submit a letter requesting such closer to trial. The revised proposed scheduling order is due by the end of the day on 4/11/2022. (Court Reporter Dale Hawkins.) Associated Cases: 1:21-cv-01042-MN et al.(mdb) |
| Apr 1, 2022 | 14 | Stipulation (6) Docket Text: STIPULATION and Order Dismissing Defendant Teva Pharmaceutical Industries Ltd. Without Prejudice and Amending Caption to Reflect Same by Neurocrine Biosciences, Inc.. (Mayo, Andrew) |
| Apr 1, 2022 | 13 | Waiver of Service Executed (1) Docket Text: WAIVER OF SERVICE returned executed by Neurocrine Biosciences, Inc.: For Teva Pharmaceuticals Development, Inc. waiver sent on 3/31/2022, answer due 5/31/2022. (Mayo, Andrew) |
| Apr 1, 2022 | 12 | Waiver of Service Executed (1) Docket Text: WAIVER OF SERVICE returned executed by Neurocrine Biosciences, Inc.: For Teva Pharmaceuticals USA, Inc. waiver sent on 3/31/2022, answer due 5/31/2022. (Mayo, Andrew) |
| Apr 1, 2022 | 11 | Waiver of Service Executed (1) Docket Text: WAIVER OF SERVICE returned executed by Neurocrine Biosciences, Inc.: For Teva Pharmaceuticals, Inc. waiver sent on 3/31/2022, answer due 5/31/2022. (Mayo, Andrew) |
| Mar 25, 2022 | N/A | Order Setting Scheduling Conference (0) Docket Text: ORAL ORDER Setting Telephonic Scheduling Conference: IT IS HEREBY ORDERED that a telephonic Scheduling Conference is set for 4/4/2022 at 11:00 AM before Judge Maryellen Noreika. Counsel shall provide a teleconference dial-in number and code for the teleconference by emailing this Court's judicial administrator. ORDERED by Judge Maryellen Noreika on 3/25/2022. (dlw) |
| Mar 24, 2022 | 9 | Text of Proposed Order (23) |
| Mar 24, 2022 | 9 | Main Document (1) Docket Text: Letter to The Honorable Maryellen Noreika from Andrew C. Mayo regarding proposed scheduling order. (Attachments: # (1) Text of Proposed Order)(Mayo, Andrew) |
| Mar 21, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED re (19 in 1:21-cv-01148-MN, 15 in 1:21-cv-01067-MN, 21 in 1:21-cv-01043-MN, 14 in 1:21-cv-01464-MN, 26 in 1:21-cv-01118-MN, 12 in 1:21-cv-01408-MN, 15 in 1:21-cv-01042-MN, 21 in 1:21-cv-01553-MN, 8 in 1:22-cv-00092-MN) Stipulation to Extend Time to submit proposed scheduling order - IT IS HEREBY ORDERED that the deadline to submit the proposal scheduling order is extended through and including 3/24/2022. ORDERED by Judge Maryellen Noreika on 3/21/2022. (dlw) |
| Mar 18, 2022 | 8 | Stipulation (5) Docket Text: STIPULATION Seeking to Extend the Deadline by which a Proposed Scheduling Order is Due, by Neurocrine Biosciences, Inc.. (Balick, Steven) |
| Mar 10, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED re (16 in 1:21-cv-01553-MN, 14 in 1:21-cv-01067-MN, 18 in 1:21-cv-01148-MN, 25 in 1:21-cv-01118-MN, 13 in 1:21-cv-01464-MN, 7 in 1:22-cv-00092-MN, 14 in 1:21-cv-01042-MN, 20 in 1:21-cv-01043-MN, 11 in 1:21-cv-01408-MN) Stipulation to Extend Time to submit a proposed scheduling order through and including 3/18/2022. ORDERED by Judge Maryellen Noreika on 3/10/2022. (dlw) |
| Mar 9, 2022 | 7 | Stipulation (5) Docket Text: STIPULATION Seeking to Extend the Deadline by which a Proposed Scheduling Order is Due, by Neurocrine Biosciences, Inc.. (Balick, Steven) |
| Feb 9, 2022 | N/A | Oral Order (0) Docket Text: ORAL ORDER - IT IS HEREBY ORDERED that, within thirty (30) days from the date of this Order, the parties shall confer regarding proposed dates in the scheduling order and shall submit a proposed order, which is also consistent with the following guidance. The parties shall provide final contentions (i.e., final infringement and invalidity contentions, as well as final non-infringement and validity contentions) around the time that fact discovery closes (i.e., several weeks prior to or after the deadline to complete fact discovery) and at least three weeks before Plaintiff serves its opening claim construction brief. Final contentions shall include a party's contentions under its proposed construction(s), as well as under the opposing construction(s) (if such an alternative contention exists). As such, the parties are encouraged to exchange proposed claim terms and proposed constructions early in the case but in no event later than necessary to allow the parties to include alternative contentions in their final contentions. The joint claim construction chart shall be due one week after the parties have completed their exchange of final contentions, and the joint claim construction brief must be filed at least three weeks before the claim construction hearing. The parties shall leave at least three weeks between the claim construction hearing and the opening of expert discovery. The parties are to use the Court's form scheduling order, which is posted at http://www.ded.uscourts.gov (see Chambers, Judge Noreika, Forms), and the parties must include a proposal for the length and timing of trial. If there are disputes or issues that the Court needs to address in the proposed scheduling order, the parties shall direct the Court to the paragraph numbers in which those appear in a cover letter to the Court. ORDERED by Judge Maryellen Noreika on 2/9/2022. (dlw) |
| Jan 26, 2022 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Assigned to Judge Maryellen Noreika. Please include the initials of the Judge (MN) after the case number on all documents filed. (rjb) |
| Jan 21, 2022 | 5 | Disclosure Statement (1) Docket Text: Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Neurocrine Biosciences, Inc.. (twk) |
| Jan 21, 2022 | 4 | Patent/Trademark Report to Commissioner (1) Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,026,931; 11,026,939; 11,040,029. (twk) |
| Jan 21, 2022 | 3 | ANDA Form (2) Docket Text: Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: December 13, 2021. Date of Expiration of the 931 Patent: August 14, 2039. Date of Expiration of the 939 Patent: September 18, 2038. Date of Expiration of the 029 Patent: October 10, 2037. Hatch-Waxman Regulatory Exclusivity Deadline: October 11, 2024. (twk) |
| Jan 21, 2022 | 2 | Magistrate Consent Forms (3) Docket Text: Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (twk) |
| Jan 21, 2022 | 1 | Civil Cover Sheet (3) |
| Jan 21, 2022 | 1 | Exhibit A (79) |
| Jan 21, 2022 | 1 | Complaint* (1) |
| Jan 21, 2022 | 1 | Main Document (20) Docket Text: COMPLAINT FOR PATENT INFRINGEMENT filed against Teva Pharmaceutical Industries Ltd., Teva Pharmaceuticals Development, Inc., Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 402, receipt number ADEDC-3786973.) - filed by Neurocrine Biosciences, Inc.. (Attachments: # (1) Exhibit A, # (2) Civil Cover Sheet)(twk) |
| Jan 21, 2022 | N/A | No Summons Issued (0) Docket Text: No Summons Issued. (twk) |
